Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 71Colorectal Neoplasms 34Rectal Neoplasms 33Esophageal Neoplasms 25Carcinoma, Non-Small-Cell Lung 24Esophageal Squamous Cell Carcinoma 23Pancreatic Neoplasms 16Stomach Neoplasms 15Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Adenocarcinoma Of Esophagus 14Ovarian Neoplasms 11Lung Neoplasms 11Colonic Neoplasms 11Carcinoma, Hepatocellular 11Sarcoma 10Prostatic Neoplasms 10Head and Neck Neoplasms 10Neoplasm Metastasis 9Urinary Bladder Neoplasms 8Uterine Cervical Neoplasms 7Recurrence 6Osteosarcoma 6Multiple Myeloma 5Fallopian Tube Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Breast Carcinoma In Situ 5Peritoneal Neoplasms 4Nasopharyngeal Carcinoma 4Locally Advanced Rectal Cancer 4

Interventions

pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Carboplatin 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Neoadjuvant Therapy × Clear all
NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Tang-Du Hospital

Phase 2 Recruiting
10 enrolled
Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
600 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡